The American Academy of Neurology has reported promising results in early trials of the drug, Epidiolex, which is 98 percent pure cannabidiol, in treating severe forms of pediatric epilepsy, including Dravet syndrome and Lennox-Gastaut syndrome.
Tag Archives: GW Pharma
Friday the 13th: Don’t Hide in the Shadows
Cannabis stocks were mostly lower today, not too surprising given the day of the week. Unfortunately, the earlier enthusiasm around the potentially game changing CARERS Act has quickly waned.
Friday Long Weekend
Volumes in the cannabis space were nonexistent. Not surprising given the general trend of Fridays and the day before a long weekend.
Wednesday’s Key Questions to Consider
This morning’s November ADP jobs report came in with more than 200,000 jobs added. The U.S. economy continues to chug along, but this report was a bit softer than expected.
Midweek Lift: Broader Markets and Cannabis Sector Showed Bump for Humpday
The S&P 500, Russell 2k and Russell MicroCap all experienced gains of > 1.7%. MJIC Marijuana Index and Benzinga 420 Marijuana Index both underperformed, with a gain of 0.09% and a decline of 1.51% respectively.
UK Cost Agency Rejects British Company GW’s Cannabis Drug
LONDON, Oct 8 (Reuters) - A pioneering cannabis drug developed by British firm GW Pharmaceuticals for treating spasticity in multiple sclerosis has been rejected as not cost-effective in the company’s home market.
Just Say No to Small Marijuana Stocks
Given the title of yesterday’s Market Musings piece and the subject of today’s, you, dear reader, could be forgiven for thinking that I have some kind of a drug problem. I can assure you that I don’t. I just have a problem with some drug stocks, both the non-conventional and more traditional.
Look Out Big Pharma: GW’s in Town
GW Pharma utilizies CBD technology in order to develop a new breakthrough treatment for pediatric epilepsy.